For the quarter ended June 2024, Bristol Myers Squibb (BMY) reported revenue of $12.2 billion, up 8.7% over the same period last year. EPS came in at $2.07, compared to $1.75 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $11.52 billion, representing a surprise of +5.93%. The company delivered an EPS surprise of +26.22%, with the consensus EPS estimate being $1.64.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall S ...

Bristol Myers Squibb (BMY) came out with quarterly earnings of $2.07 per share, beating the Zacks Consensus Estimate of $1.64 per share. This compares to earnings of $1.75 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 26.22%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $4.55 per share when it actually produced a loss of $4.40, delivering a surprise of 3.30%.Over the last four quart ...

Exhibit 99.1 1 Bristol Myers Squibb Reports Second Quarter Financial Results for 2024 Results Underscore Continued Progress on Commercial Execution, Driving the Growth Portfolio and Pipeline Advancement • Second Quarter Revenues were $12.2 Billion, increasing 9% (+11% Adjusting for Foreign Exchange) • Growth Portfolio Revenues were $5.6 Billion, increasing 18% (+21% Adjusting for Foreign Exchange) • GAAP EPS was $0.83 and Non-GAAP EPS was $2.07; Includes Net Impact of $(0.04) Per Share for GAAP EPS and Non- ...

The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, on Dec. 27, 2023.Bristol Myers Squibb on Friday reported second-quarter earnings and revenue that topped expectations and raised its full-year guidance as the drugmaker moves to slash costs.The pharmaceutical giant raised its full-year revenue forecast to an increase in the "upper end" of the low single-digit range. That compares to its previous guidance in April of a low single-digit increase in sale ...

Bristol Myers Squibb (BMY) announced that the European Medicines Agency (EMA) has validated its type II variation application for immunotherapy drug Opdivo (nivolumab), in combination with Yervoy (ipilimumab).The application seeks approval of Opdivo plus Yervoy as a potential first-line treatment option for adult patients with unresectable or advanced hepatocellular carcinoma (HCC) who have not received any prior systemic therapy.The application is based on results from the late-stage CheckMate -9DW trial, ...

Defensive stocks are stealing the spotlight again following Fed Chair Jerome Powell’s recent comments.In his address at the Economic Club of Washington D.C., Powell talked about the precarious state of the economy. His remarks emphasized the stickiness in inflation, policy uncertainties, and large deficits amid full employment. Hence, given the breadth of variables impacting the economy, it seems like a tough road ahead for those expecting quick monetary easing. The Federal Reserve plans to approach policy ...

The market expects Bristol Myers Squibb (BMY) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be rel ...

The latest trading session saw Bristol Myers Squibb (BMY) ending at $42.39, denoting a -1.76% adjustment from its last day's close. This change lagged the S&P 500's 0.78% loss on the day. Elsewhere, the Dow saw a downswing of 1.29%, while the tech-heavy Nasdaq depreciated by 0.7%.Prior to today's trading, shares of the biopharmaceutical company had gained 5.73% over the past month. This has outpaced the Medical sector's gain of 2.23% and the S&P 500's gain of 2.14% in that time.Market participants will be c ...

hapabapa When looking at different pharmaceutical stocks, we see several companies rather struggling in the last few years. Of course, not every company and stock is struggling - Novo Nordisk (NVO) and Eli Lilly (LLY) for example, continue to rush from all-time high to all-time high. But stocks like Pfizer (PFE) and Bristol-Myers Squibb (NYSE:BMY) are declining lower and lower in the last few quarters. And the S&P Pharmaceutical ETF barely moved in the last five years while the S&P 500 (SPY) rushed from all ...

Andre Banyai/iStock via Getty Images BMY's Investment Thesis Is Closely Tied To The Potential Reversal In Its Patent Cliff & Rich Dividend Yields We previously covered Bristol-Myers Squibb Company (NYSE:BMY) in April 2024, discussing why we had finally rated the stock as a Buy as it offered a relatively rich forward dividend yield of 5.02% at the time of writing with the Seeking Alpha Quant still grading its payout safety as B-. Combined with its promising profitability metrics and its overly discounted ...